Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cyclerion Therapeutics Inc | CYCN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3.04 | 04:09:52 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.04 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.7501 - 6.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 3.04 | USD |
Cyclerion Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 8.24M | 2.71M | - | 0 | -5.26M | -1.94 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Cyclerion Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYCN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.49 | 3.50 | 2.77 | 3.21 | 1,605 | -0.45 | -12.89% |
| 1 Month | 3.32 | 3.98 | 2.77 | 3.17 | 3,260 | -0.28 | -8.43% |
| 3 Months | 2.99 | 4.00 | 2.645 | 3.16 | 2,933 | 0.05 | 1.67% |
| 6 Months | 3.05 | 5.25 | 1.7501 | 3.23 | 5,333 | -0.01 | -0.33% |
| 1 Year | 5.60 | 6.75 | 1.7501 | 4.63 | 20,112 | -2.56 | -45.71% |
| 3 Years | 60.20 | 97.20 | 1.7501 | 47.55 | 283,672 | -57.16 | -94.95% |
| 5 Years | 308.40 | 349.20 | 1.7501 | 66.04 | 344,541 | -305.36 | -99.01% |
Cyclerion Therapeutics Description
| Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others. |
